Thanks Dungiven- that is a very interesting article.
I'm more interested in the competition rather than the potential revenue mentioned.
Specifically Merks drug "Sprifermin" which had successful Phase 2 trials with 549 patients and was licensed to a company called Trial Spark for an undisclosed sum in Jan this year.
Does anyone know what's happening with this particular drug?
Competition???, page-13
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.005(2.13%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $63.43K | 270.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 213534 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 76890 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |